MX2021000347A - Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. - Google Patents
Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.Info
- Publication number
- MX2021000347A MX2021000347A MX2021000347A MX2021000347A MX2021000347A MX 2021000347 A MX2021000347 A MX 2021000347A MX 2021000347 A MX2021000347 A MX 2021000347A MX 2021000347 A MX2021000347 A MX 2021000347A MX 2021000347 A MX2021000347 A MX 2021000347A
- Authority
- MX
- Mexico
- Prior art keywords
- tgfî21
- isoform
- affinity
- inhibitors
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696752P | 2018-07-11 | 2018-07-11 | |
| US201862718196P | 2018-08-13 | 2018-08-13 | |
| US201862737534P | 2018-09-27 | 2018-09-27 | |
| US201862758180P | 2018-11-09 | 2018-11-09 | |
| US201962810263P | 2019-02-25 | 2019-02-25 | |
| US201962827552P | 2019-04-01 | 2019-04-01 | |
| PCT/US2019/041373 WO2020014460A1 (en) | 2018-07-11 | 2019-07-11 | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000347A true MX2021000347A (es) | 2021-04-19 |
Family
ID=67470735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000347A MX2021000347A (es) | 2018-07-11 | 2019-07-11 | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12252531B2 (enExample) |
| EP (1) | EP3820508A1 (enExample) |
| JP (2) | JP7540994B2 (enExample) |
| KR (1) | KR102891320B1 (enExample) |
| CN (1) | CN112996535B (enExample) |
| AU (1) | AU2019302679B2 (enExample) |
| BR (1) | BR112021000353A2 (enExample) |
| CL (1) | CL2021000073A1 (enExample) |
| CO (1) | CO2021000419A2 (enExample) |
| IL (1) | IL279914A (enExample) |
| MA (1) | MA53125A (enExample) |
| MX (1) | MX2021000347A (enExample) |
| PH (1) | PH12021550020A1 (enExample) |
| SG (1) | SG11202013231SA (enExample) |
| TW (1) | TWI923546B (enExample) |
| WO (1) | WO2020014460A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| KR102891320B1 (ko) | 2018-07-11 | 2025-11-28 | 스칼러 락, 인크. | 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도 |
| SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| CN120022360A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CA3167427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
| AU2021239667B2 (en) * | 2020-03-19 | 2026-05-07 | Chugai Seiyaku Kabushiki Kaisha | Biomarkers for predicting the response to checkpoint inhibitors |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| TW202317185A (zh) * | 2021-06-18 | 2023-05-01 | 美商健臻公司 | 抗ＴＧＦ－β抗體配製品及其用途 |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| CN113604214B (zh) * | 2021-08-09 | 2023-07-14 | 青岛大学 | 一种高稳定性溶瘤肽荧光探针及其制备方法和应用 |
| CN116262137A (zh) * | 2021-12-14 | 2023-06-16 | 四川大学 | 一种同时杀伤肿瘤和改善免疫微环境的抗肿瘤联合用药物 |
| CN114236137A (zh) * | 2021-12-17 | 2022-03-25 | 中山大学·深圳 | 一种转化生长因子β的体外检测试剂盒及其应用 |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| CN120418286A (zh) | 2023-01-09 | 2025-08-01 | 北京拓界生物医药科技有限公司 | TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途 |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JPH11507843A (ja) | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6248723B1 (en) | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| PE20020132A1 (es) | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
| JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | ＴＧＦ−β活性化制御領域の切断面を認識する抗体 |
| CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US9642873B2 (en) | 2010-05-04 | 2017-05-09 | Sirnaomics, Inc. | Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| JP6495884B2 (ja) | 2013-03-11 | 2019-04-03 | ジェンザイム・コーポレーション | 改変抗ｔｇｆベータ抗体および抗原結合フラグメント |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| WO2015171691A2 (en) | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| JP6836998B2 (ja) | 2015-03-02 | 2021-03-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ＴＧＦ−β阻害剤 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| EP3307772B1 (en) | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
| JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| RU2018131123A (ru) | 2016-02-17 | 2020-03-17 | Новартис Аг | Антитела к tgf-бета2 |
| ES2951648T3 (es) | 2016-03-11 | 2023-10-24 | Scholar Rock Inc | Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas |
| US10649198B2 (en) * | 2016-03-11 | 2020-05-12 | Battelle Memorial Institute | Sample processing and analysis methods and apparatus |
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| EP3484499A4 (en) | 2016-07-14 | 2020-05-13 | Scholar Rock, Inc. | TGFB ANTIBODIES, METHODS AND USE |
| CN110382530A (zh) | 2017-01-06 | 2019-10-25 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
| EP3571227A1 (en) | 2017-01-20 | 2019-11-27 | Sanofi | Anti-tgf-beta antibodies and their use |
| EP3658583A1 (en) | 2017-07-28 | 2020-06-03 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
| KR102891320B1 (ko) | 2018-07-11 | 2025-11-28 | 스칼러 락, 인크. | 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도 |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
-
2019
- 2019-07-11 KR KR1020217003926A patent/KR102891320B1/ko active Active
- 2019-07-11 SG SG11202013231SA patent/SG11202013231SA/en unknown
- 2019-07-11 EP EP19745926.6A patent/EP3820508A1/en active Pending
- 2019-07-11 AU AU2019302679A patent/AU2019302679B2/en active Active
- 2019-07-11 MX MX2021000347A patent/MX2021000347A/es unknown
- 2019-07-11 MA MA053125A patent/MA53125A/fr unknown
- 2019-07-11 TW TW108124516A patent/TWI923546B/zh active
- 2019-07-11 WO PCT/US2019/041373 patent/WO2020014460A1/en not_active Ceased
- 2019-07-11 JP JP2021500434A patent/JP7540994B2/ja active Active
- 2019-07-11 US US17/258,771 patent/US12252531B2/en active Active
- 2019-07-11 BR BR112021000353-3A patent/BR112021000353A2/pt unknown
- 2019-07-11 CN CN201980059305.0A patent/CN112996535B/zh active Active
-
2021
- 2021-01-03 IL IL279914A patent/IL279914A/en unknown
- 2021-01-04 PH PH12021550020A patent/PH12021550020A1/en unknown
- 2021-01-11 CL CL2021000073A patent/CL2021000073A1/es unknown
- 2021-01-18 CO CONC2021/0000419A patent/CO2021000419A2/es unknown
-
2024
- 2024-04-22 JP JP2024068880A patent/JP7858715B2/ja active Active
-
2025
- 2025-02-04 US US19/045,513 patent/US20250257125A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021000419A2 (es) | 2021-01-29 |
| KR102891320B1 (ko) | 2025-11-28 |
| CN112996535A (zh) | 2021-06-18 |
| IL279914A (en) | 2021-03-01 |
| WO2020014460A1 (en) | 2020-01-16 |
| KR20210058811A (ko) | 2021-05-24 |
| EP3820508A1 (en) | 2021-05-19 |
| TW202005981A (zh) | 2020-02-01 |
| CN112996535B (zh) | 2026-04-24 |
| JP7540994B2 (ja) | 2024-08-27 |
| JP7858715B2 (ja) | 2026-05-14 |
| PH12021550020A1 (en) | 2021-09-13 |
| CL2021000073A1 (es) | 2021-07-30 |
| AU2019302679B2 (en) | 2026-04-23 |
| SG11202013231SA (en) | 2021-01-28 |
| US20210122814A1 (en) | 2021-04-29 |
| JP2024099673A (ja) | 2024-07-25 |
| TWI923546B (zh) | 2026-05-01 |
| JP2021531254A (ja) | 2021-11-18 |
| US12252531B2 (en) | 2025-03-18 |
| MA53125A (fr) | 2021-05-19 |
| US20250257125A1 (en) | 2025-08-14 |
| WO2020014460A8 (en) | 2020-02-13 |
| BR112021000353A2 (pt) | 2021-08-03 |
| CA3105988A1 (en) | 2020-01-16 |
| AU2019302679A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550020A1 (en) | High-affinity, isoform-selective tgf#1 inhibitors and use thereof | |
| WO2020014473A8 (en) | TGFβ1 INHIBITORS AND USE THEREOF | |
| IL280963A (en) | Anti-5gdf1 antibodies, compounds and methods of use | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12020551716A1 (en) | Anti-ror antibody constructs | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| ZA202102034B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| CY1125076T1 (el) | Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτων | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| PH12022551150A1 (en) | Biparatopic cd73 antibodies | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| ZA202309516B (en) | Anti-ccr8 antibodies | |
| MA53765B2 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| MX2021007848A (es) | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. |